Cell line · CVCL_8800
OCI-Ly3
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma activated B-cell type. 40 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. OCI-Ly3. Cell lines, record CVCL_8800. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_8800
On this page
Cell line
As Cellosaurus gives it.
- Name
- OCI-Ly3
- Accession
- CVCL_8800
- RRID
- RRID:CVCL_8800
- Synonyms
- OCI-LY3, OCI-ly3, OCI-LY-3, Oci-Ly-3, OCI-Ly 3, OCILY-3, OCI-Ly03, OCI Ly3, OCILY3, Ly3, LY3
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 52Y
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma activated B-cell type (NCIt C36081); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Bone marrow (in situ)
- Entry created
- 2012-06-06
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | A cell line, now termed GNE-587170 (Cellosaurus=CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known. |
Source Cellosaurus
Papers40
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models. | Blood Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma. | Apoptosis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor - a preliminary analysis. | Ann Hematol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. | Leukemia | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. | J Exp Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 40
See all 40 papersRelatives0
None in this release.
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| DSMZ | ACC-761 |
Source DSMZ
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8800
GET https://conductscience.org/api/cell-lines/v1/CVCL_8800/papers?page=2